Analysts Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) PT at $90.50

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has received a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, four have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $90.50.

Several equities analysts have issued reports on the stock. Oppenheimer upped their target price on shares of Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, August 12th. Wall Street Zen downgraded shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. HC Wainwright reiterated a “buy” rating and issued a $88.00 price target on shares of Tarsus Pharmaceuticals in a research note on Thursday, July 9th. Mizuho decreased their price objective on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Finally, Guggenheim lowered their price objective on shares of Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating on the stock in a research report on Tuesday, July 21st.

Insider Activity at Tarsus Pharmaceuticals

In other news, insider Jeffrey S. Farrow sold 14,396 shares of the firm’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $60.95, for a total value of $877,436.20. Following the transaction, the insider directly owned 56,801 shares in the company, valued at $3,462,020.95. This trade represents a 20.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Katherine Goodrich sold 2,954 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $62.08, for a total value of $183,384.32. Following the completion of the transaction, the director owned 2,233 shares in the company, valued at approximately $138,624.64. This trade represents a 56.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 39,850 shares of company stock worth $2,452,821. Company insiders own 9.64% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Parallel Advisors LLC increased its position in shares of Tarsus Pharmaceuticals by 139.2% during the 1st quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock valued at $35,000 after purchasing an additional 291 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of Tarsus Pharmaceuticals by 367.1% in the first quarter. PNC Financial Services Group Inc. now owns 710 shares of the company’s stock worth $50,000 after buying an additional 558 shares during the last quarter. Comerica Bank boosted its holdings in shares of Tarsus Pharmaceuticals by 470.0% in the fourth quarter. Comerica Bank now owns 855 shares of the company’s stock worth $70,000 after buying an additional 705 shares during the last quarter. Truvestments Capital LLC boosted its holdings in shares of Tarsus Pharmaceuticals by 106.1% in the fourth quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock worth $74,000 after buying an additional 468 shares during the last quarter. Finally, State of Wyoming bought a new stake in Tarsus Pharmaceuticals during the second quarter valued at approximately $103,000. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Up 1.7%

TARS stock opened at $72.70 on Friday. Tarsus Pharmaceuticals has a 1-year low of $48.20 and a 1-year high of $85.25. The business has a fifty day moving average price of $63.45 and a 200-day moving average price of $65.09. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.20 and a quick ratio of 3.17. The stock has a market capitalization of $3.19 billion, a P/E ratio of -66.70 and a beta of 0.53.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative net margin of 7.67% and a negative return on equity of 13.53%. The business had revenue of $173.91 million for the quarter, compared to the consensus estimate of $169.65 million. Equities analysts forecast that Tarsus Pharmaceuticals will post -2.06 earnings per share for the current fiscal year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.